Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motexafin Gadolinium and Docetaxel in Advanced NSCLC
NCT00373204Phase 2Terminated
- Sponsor
- Pharmacyclics
- Start
- May 2006
- Primary completion
- Feb 2008
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of motexafin gadolinium in non-small cell lung cancer (NSCLC), sponsored by Pharmacyclics. Primary endpoint: Complete and Partial Response Rate. Started May 2006; status: terminated.
02
Drugs
motexafin gadolinium
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00373204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00373204.